Clinical significance of antinucleosome antibodies in patients with “early” systemic lupus erythematosus
https://doi.org/10.14412/1995-4484-2007-41-46
Abstract
Objective. To assess clinical and diagnostic value of antibodies to nucleosom e in «early» systemic lupus erythematosus (SLE).
Material and methods. 37 pts with «early « SLE were included. The control groups consisted of 36 pts with rheumatoid arthritis (RA), 31 pts with primary Sjogren›s syndrom e (SS) and 45 healthy subjects. Concentration of antibodies to nucleosom e and to double stranded deoxyribonucleic acid (dsDNA) was measured with enzyme immunoassay (EIA).
Results. The level of antinucleosom e antibodies in SLE pts (64,5 ± 53,7 U/ml) was significantly higher than in RA and SS pts (JO, 9 ±23,7 U/ml; p<0,05 и 15,7 ±11,5 U/ml respectively; p<0,05) or in donors (8,3 ± 5,2 U/ml; p<0,05). Correlation was found between level of antibodies to nucleosom e and antibodies to dsDNA (χ2 = 14,4; p<0,05). Sensitivity (87,5%) and specificity (95%) of antinucleosom e antibodies were similar to anti-dsDNA antibodies (85,2% и 93% respectively). Simultaneous evaluation of antibodies to nucleosom e and dsDNA provided 97 % specificity. There was a correlation between the level of antibodies to nucleosom e and disease activity in SLE (p<0,0001).
Conclusion. Evaluation of antinucleosom e antibodies with EIA is a sensitive and specific serological test for early SLE diagnosis. The antibodies to nucleosom e reflect activity of SLE
About the Authors
M. A. Kotovskaya
ГУ Институт ревматологии РАМН, Москва
Russian Federation
Russian Federation
S. K. Solovjov
ГУ Институт ревматологии РАМН, Москва
Russian Federation
Russian Federation
N. Y. Nikishina
ГУ Институт ревматологии РАМН, Москва
Russian Federation
Russian Federation
E. L. Nasonov
ГУ Институт ревматологии РАМН, Москва
Russian Federation
Russian Federation
References
1. Насонова В.А., Насонов Е.Л. Рациональная фармакотерапия ревматических заболеваний. Рук. для практикующих врачей. М., Литтерра, 2003, 507.
2. Pisetsky D.S. Anti-DNA and autoantibodies. Curr. Opin. Rheumatol., 2000, 12, 364-368.
3. Villarr eal G.M., Drenkard C.,Villa A.R. et al. Prevalence of 13 autoantibodies and of the16/6 and related pathogenic idiotypes in 465 patients with systemic lupus erythematosus and their relationship with disease activity. Lupus, 1997, 6, 425-435.
4. Amoura Z., Piette J.C., Bach J.F., Koutouzov S. The key role of nucleosom es in lupus. Arthr. Rheum. 1999, 42, 833-843.
5. Amoura Z., Koutouzov S., Piette J.C. The role of nucleosom e in lupus. Curr. Opin. Rheumatol., 2000, 12, 369-373.
6. Bur lin gam e R.W., Boey M.L., Star kebaum G., Rubin R.L. The central role of chromatin in auto
7. Cairn s A.P., McMillan S.A., Cro ckar d A.D. et al. Antinucleosome antibodies in the diagnosis of systemic lupus erythematosus. Ann. Rheum. Dis., 2003, 62, 272-273.
8. Chirar dello A., Doria A., Zam pieri S. et al. Antinucleosom e antibodies in SLE: a two-year fol
9. Junkenen H., Salonen EM., Walle T.K., Miettinen A. Anti-nucleosom e antibodies in the diagnosis of systemic lupus erythematosus. Scan. J. Rheumatol., 2005, 34 (2), 122-124.
10. Min D.J., Kim S.J., Park S.H. et al. Anti-nucleo
11. Simon J.A., Cabiedes J., Orti z E. et al. Anti-nucleosom e antibodies in patients with systemic lupus erythematosus of recent onset. Potential util
12. Su er W., Dahnrich C., Schumberger W., Stocker W. Autoantibodies in SLE but not in scleroderma react with protein-stripped nucleosom es. J. Autoimmun., 2004, 22, 325-334.
13. Sa llai K., Nagy E., Derfalvy B. et al. Antinucleosome antibodies and decreased deoxyribonuclease activity in sera of patients with systemic lupus eruthemato
14. Amoura Z., Chabre H., Koutou zov S. et al.Nucleosom e-r estri cted anti bodies ar e detected before anti-ds DNA and/or antihistones antibodies in serum of MRL-Mp lpr/lpr and +/+ mice and are present in kidney eluates of lupus mice with protein
15. Decker P. Nucleosom e autoantibodies. Clin. Chim. Acta, 2006, 366, 48-60.
16. Насонова В А Системная красная волчанка. В кн. «Клиническая ревматология» (под ред . В.А . Насоновой,М. Г Астапенко) М., 1989, 143
17. Bom bardier C., Gladman DD., Urowitz MB. et al. Derivation of the SLEDAI. Arthr. Rheum., 1992, 35, 6, 630-640.
18. Gladman DD., Ibanez D., Urowitz MB SLEDAI 2000. J. Rheumatol., 2002;29:288-291.
19. Villalta D., To zzori R., Bizzaro N. et al. The rel
20. Vamvakas E.C. Meta-analyze of studies of the diag
21. Yin Su, Ru-Lin Jia, Lei Han, Zhan-Guo Li. Role of anti-nucleosom e antibody in the diagnosis of systemi c lupus erythemato sus. Clin . Immuno l., 2007, 122, 115–120.
Review
For citations:
Kotovskaya M.A., Solovjov S.K., Nikishina N.Y., Nasonov E.L. Clinical significance of antinucleosome antibodies in patients with “early” systemic lupus erythematosus. Rheumatology Science and Practice. 2007;45(4):41-46. (In Russ.) https://doi.org/10.14412/1995-4484-2007-41-46
Views:
721
Email this article 